Heron Therapeutics, Inc. (HRTX)

Price$0.43

Value ScoreC

Growth ScoreC

Momentum ScoreF

Favorite Metrics

Price vs S&P 500 (26W)-71.08%

Price vs S&P 500 (4W)-64.67%

VGM Score32.08

Market Capitalization$80.90M

All Metrics

Book Value / Share (Quarterly)$0.05

P/TBV (Annual)15.26x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)12.88%

Cash Flow / Share (Quarterly)$-0.11

Price vs S&P 500 (YTD)-75.28%

Gross Margin (TTM)71.12%

Net Profit Margin (TTM)-20.53%

EPS (TTM)$-0.18

10-Day Avg Trading Volume5.27M

EPS Excl Extra (TTM)$-0.18

Revenue Growth (5Y)11.82%

EPS (Annual)$-0.12

ROI (Annual)-13.03%

Gross Margin (Annual)73.31%

Net Profit Margin (5Y Avg)-106.84%

Cash / Share (Quarterly)$0.24

Revenue Growth QoQ (YoY)-10.78%

ROA (Last FY)-7.89%

Revenue Growth TTM (YoY)1.48%

EBITD / Share (TTM)$-0.11

ROE (5Y Avg)-382.07%

Operating Margin (TTM)-14.46%

Cash Flow / Share (Annual)$-0.15

P/B Ratio8.85x

P/B Ratio (Quarterly)16.51x

Net Income / Employee (Annual)$-157,800

EV / Revenue (TTM)1.30x

Net Interest Coverage (TTM)-1.64x

ROA (TTM)-12.59%

EV / EBITDA (TTM)83.37x

EPS Incl Extra (Annual)$-0.12

Current Ratio (Annual)2.48x

Quick Ratio (Quarterly)1.42x

3-Month Avg Trading Volume2.38M

52-Week Price Return-78.63%

Revenue / Employee (TTM)$1,177,400

Tangible BV / Share (Quarterly)$-0.20

P/S Ratio (Annual)0.52x

Asset Turnover (Annual)0.61x

52-Week High$2.30

Operating Margin (5Y Avg)-103.72%

EPS Excl Extra (Annual)$-0.12

CapEx CAGR (5Y)-45.85%

Tangible BV CAGR (5Y)-36.47%

26-Week Price Return-63.16%

Quick Ratio (Annual)1.42x

13-Week Price Return-58.10%

Total Debt / Equity (Annual)9.81x

Current Ratio (Quarterly)2.53x

Enterprise Value$196.41M

Revenue / Share Growth (5Y)-0.97%

Asset Turnover (TTM)0.61x

Book Value / Share Growth (5Y)-56.22%

Revenue / Employee (Annual)$1,210,200

Inventory Turnover (Annual)0.57x

Pretax Margin (Annual)-13.04%

Cash / Share (Annual)$0.25

3-Month Return Std Dev123.19%

Gross Margin (5Y Avg)58.20%

Net Income / Employee (TTM)$-241,700

ROE (Last FY)-140.90%

Net Interest Coverage (Annual)0.61x

EPS Basic Excl Extra (Annual)$-0.12

P/FCF (TTM)60.78x

Receivables Turnover (TTM)1.86x

Total Debt / Equity (Quarterly)15.50x

EPS Incl Extra (TTM)$-0.18

Receivables Turnover (Annual)1.84x

ROI (TTM)-18.61%

P/S Ratio (TTM)0.54x

Pretax Margin (5Y Avg)-106.84%

Revenue / Share (Annual)$0.93

Tangible BV / Share (Annual)$0.11

Forward P/E100.01x

Price vs S&P 500 (52W)-103.00%

Year-to-Date Return-67.12%

5-Day Price Return-48.33%

EPS Normalized (Annual)$-0.12

ROA (5Y Avg)-41.62%

Net Profit Margin (Annual)-13.04%

Month-to-Date Return-50.88%

Cash Flow / Share (TTM)$-0.93

EBITD / Share (Annual)$-0.07

Operating Margin (Annual)-8.96%

LT Debt / Equity (Annual)9.81x

ROI (5Y Avg)-73.08%

LT Debt / Equity (Quarterly)15.50x

EPS Basic Excl Extra (TTM)$-0.18

P/B Ratio (Annual)16.63x

Inventory Turnover (TTM)0.58x

Pretax Margin (TTM)-20.53%

Book Value / Share (Annual)$0.08

Price vs S&P 500 (13W)-66.35%

Beta1.72x

P/FCF (Annual)9.00x

Revenue / Share (TTM)$0.79

ROE (TTM)-223.39%

52-Week Low$0.42

vGradeC

gGradeC

mGradeF

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.04est. -0.02

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.20

4.11

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
HRTXHeron Therapeutics, Inc.	C	C	F	$0.43
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Heron Therapeutics is a commercial-stage biopharmaceutical company with a portfolio of marketed products including APONVIE, SUSTOL, ZYNRELEF, and CINVANTI. The company develops innovative treatments to address unmet patient needs.